Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice

AZD1222 (ChAdOx1 nCoV-19) is a COVID-19 vaccine that is not yet licensed for use during pregnancy. To support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies, a non-clinical developmental and reproductive toxicity study was performed to evaluate its effects on fertility and reproductive processes of female CD-1 mice during the embryofetal development phase, and postnatal outcomes during the littering phase. Immunogenicity assessments were also made in dams, fetuses, and pups. There were no vaccine related unscheduled deaths throughout the study. Furthermore, there were no vaccine-related effects on female reproduction, fetal or pup survival, fetal external, visceral, or skeletal findings, pup physical development, and no abnormal gross pathology findings in pups or dams. Antibody responses raised in dams were maintained throughout gestation and postnatal periods, and seroconversion in fetuses and pups indicate placental and lactational transfer of immunoglobulins. Together with clinical data from non-pregnant people, these results support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies.

Automated summary

The non-clinical study on AZD1222 showed no adverse effects on female reproduction, fetal or pup survival, and development. Antibody responses in dams were maintained throughout gestation and postnatal periods, and seroconversion in fetuses and pups indicated the transfer of immunoglobulins through placental and lactational routes. These results, combined with clinical data from non-pregnant individuals, support the inclusion of pregnant and breastfeeding individuals in AZD1222 clinical studies.